RxDoctor Payments Data

Elizabeth Medina

Adult Health · Jenkintown, PANPI 1538466529

Payments from drug & device makers

$3,439in general payments, 2019–2025

Across 171 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$719
  • Kestra Medical Technology Services, Inc.$333
  • AstraZeneca$293
  • Pfizer$231
  • Johnson & Johnson$199
  • E.r. Squibb & Sons, L.L.C.$198
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,439 in reported general payments places this provider in the 85th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,976
Medicare patients
62
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$146,692
XareltoRivaroxaban33$30,886
EntrestoSacubitril/Valsartan13$11,216
Repatha SureclickEvolocumab15$11,144
FarxigaDapagliflozin Propanediol11$10,793
Atorvastatin Calcium177$2,634
Metoprolol Succinate146$2,480
Valsartan26$1,151
Rosuvastatin Calcium55$1,127
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,111
Losartan Potassium81$1,045
Amiodarone Hcl20$925
Flecainide Acetate12$914
Carvedilol61$811
Amlodipine Besylate103$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$231$146,692132 claims
Johnson & JohnsonXarelto$199$30,88633 claims
NovartisEntresto$719$11,21613 claims
AstraZenecaFarxiga$293$10,79311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Jenkintown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →